Could a tiny dose of radiation reboot cancer immunotherapy?

NCT ID NCT07164690

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase II trial tests whether a single low dose of radiation to all visible tumors can help immunotherapy work again in people with advanced esophageal cancer that has stopped responding to standard treatment. Thirty-two adults will receive the radiation and continue their original immunotherapy. The study will track how long the cancer stays controlled and whether the combination is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: low-dose radiation therapy
What this could lead to: If successful, this approach could help restore the effectiveness of immunotherapy in patients whose esophageal cancer has stopped responding to standard treatment.
What could go wrong: This is a small, early-phase trial with only 32 participants and no comparison group. The benefit may be modest, and there are risks like fistula or bleeding from radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL ADENOCARCINOMA RADIOTHERAPY

More trials for these conditions

Other studies related to the condition(s) this trial covers.